Empirico

News

In its second pipeline-expanding deal in 24 hours, GSK has licensed rights to a drug for COPD from US biotech Empirico for $85m upfront.

Oncology

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.